CCBPSTUDY

Realizing the Dream of Precision Medicine for Neurodegenerative Diseases

[Benjamin Stecher @Neuronologist1]

The second from @AlbertoEspay and @andrea_sturchio summarizes the key points leading some to question our understanding of the toxic role of proteins in neurodegenerative diseases.

https://t.co/qrN82lKLbH

[Benjamin Stecher @Neuronologist1]

Two new interesting articles added today to the @ccbpstudy blog.

The first from @LucaMarsili1 asks what we need to do to be able to translate all that we are learning about the genetics of Parkinson's disease into therapies.

https://t.co/05xCJ1tcVc

[Benjamin Stecher @Neuronologist1]

And then I look at the distinctions we have made between symptoms and disease and ask what is needed to properly separate the two.

https://t.co/JKLcCOp211

[Benjamin Stecher @Neuronologist1]

In the next post I look at biomarkers and why they are so critical to the development of new therapies.

https://t.co/BpccuxySgX

[Benjamin Stecher @Neuronologist1]

Next @AlbertoEspay covers how we have classified neurodegenerative diseases and what is needed to enable us to properly identify what is really going wrong in each individual.

https://t.co/XNAKdBSl0b

[Benjamin Stecher @Neuronologist1]

In the first post @AlbertoEspay looks at the future of clinical trials and why we need to rethink our approach to how we study aging.

https://t.co/OISoDw9ozk

[Benjamin Stecher @Neuronologist1]

Happy to announce the launch of the CCBP Blog. On it the team @ccbpstudy will be covering topics related to aging, neurodegeneration, longitudinal studies, biomarkers, drug repurposing and more.

Below is an overview of the first entries...

https://t.co/RSgdnPDeNF

[Benjamin Stecher @Neuronologist1]

Thank you to @AlbertoEspay @andrea_sturchio @LucaMarsili1 and the entire team @ccbpstudy @uofcincy @uofcincyfound and all the contributors for embarking on this pioneering work.

For anyone interested in getting involved go to https://t.co/UYMu7NaW9h to find out more.

[Benjamin Stecher @Neuronologist1]

But it won't be enough. 80 million people live with a neurodegenerative disease, with many more to come. Institutions and industry around the world need to join in similar studies if we are ever going to understand and treat what the ravages of time inflict on our brains.

[Benjamin Stecher @Neuronologist1]

What we have done so far has not worked, biology and neurodegeneration are too complex for us to pin our hopes on loose affiliations, we need precise therapies matched to specific targets to give us the best shot possible of stopping or slowing the degenerating human brain.

[Benjamin Stecher @Neuronologist1]

Like any exploration into the unknown, we don't quite know what we'll find or where this study will take us, but the goal is to discover specific abnormal biological signals in small groups of individuals that we can match to therapies.

[Benjamin Stecher @Neuronologist1]

CCBP in a nutshell: 5,000 people (2000 people with any form of Parkinsonism, 2000 with any form of dementia, 1000 healthy controls) followed and samples collected for at least the next 10 years, then stripped of their diagnostic label, allowing biology guide discovery.

[Benjamin Stecher @Neuronologist1]

The CCBP methods paper is finally here!

Imho, this is what is needed if we are ever going to understand ourselves, our brains, and what happens as we age -studies of large groups of individuals, without preconceived notions about what we expect to find.

https://t.co/LACQSJhAOp

[CCBPSTUDY @ccbpstudy]

And here it is in simplified Chinese characters...

https://t.co/MOlhsmR6P9

[CCBPSTUDY @ccbpstudy]

Happy to announce that our website is now available in 4 out of 5 of the world's most widely used languages. This is in recognition of the fact that neurodegenerative diseases know no borders and will require global collaboration to properly treat.

https://t.co/C2Up7sYysB

[CCBPSTUDY @ccbpstudy]

Here it is in Arabic...

https://t.co/NMYLtsh0ig

[Benjamin Stecher @Neuronologist1]

Announcement: The Cincinnati Cohort Biomarker Program's website is now live! Click to learn more about this program taking a new approach to how we study and ultimately treat neurodegenerative diseases. More updates to come, follow along @ccbpstudy.

https://t.co/G3itIbQMAD

[Abhimanyu Mahajan @AMahajanMD]

The Cincinnati Cohort Biomarker Program (⁦⁦@ccbpstudy⁩) website is now up! The first step by @uofcincy towards precision medicine in #neurodegeneration. #Neurology https://t.co/9DAkwAd2Ji